NCT02712905 2025-11-04An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated116 enrolled 36 charts
NCT02663518 2024-05-10A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsPfizerPhase 1 Terminated249 enrolled 43 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT03588936 2021-10-11Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic TransplantMedical College of WisconsinPhase 1 Terminated2 enrolled
NCT02599649 2020-01-14Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)M.D. Anderson Cancer CenterPhase 2 Terminated10 enrolled 8 charts